ClinicalTrials.gg
RecruitingNCT07238868Updated Nov 20, 2025

An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

A Phase 2 interventional study of CB03-154 in Focal Epilepsy, sponsored by Shanghai Zhimeng Biopharma, Inc.. Recruiting at 1 site in Australia. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2025, registered Nov 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Epilepsies, Partial with a site in Australia — 8 open to participants now, 9 under way, 4 of them phase 3. Epilepsies, Partial · Australia.

Planned enrollment
16th of 20
144 · median 319
Started
2025
with 1 other
Phase 2
8 of 22
5 open now
Registered
20th of 22
by date
Lead sponsor
2 of 22
Shanghai Zhimeng Biopharma, Inc.

Among the 22 studies in Epilepsies, Partial with a site in Australia, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2025, is one of 8 in phase 2, and was the 20th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

8 of the 22 studies in Epilepsies, Partial with a site in Australia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Epilepsies, Partial with a site in Australia, or all of them as a file.
02

Study summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Focal Epilepsy.

Read the detailed description

This is an open-label extension study based on the Phase 2 clinical trial CB03-154-EP201. The study aims to assess the long-term safety, tolerability, efficacy, and pharmacokinetics (PK) of CB03-154 at a maximum dose of 20 mg administered orally once daily (QD) in patients with epilepsy. Eligible subjects are those who successfully completed the prior CB03-154-EP201 study without early discontinuation. The treatment in this extension study will last for up to two years.

03

Conditions studied

  • Focal Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. The subject must be properly informed of the nature and risks of the study and give in writing, prior to entering the study.

    2. Subject must have successfully completed the DBP and have not terminated early from Study CB03-154-EP201, met all eligibility requirements, and had no important protocol deviations (in the opinion of the sponsor) or AEs (in the opinion of the investigator) that would preclude the subject's entry into the long-term extension study, and judged to be efficacious based on the blinded data review (in the opinion of the investigator).

    3. In the opinion of the investigator, the subject is able to understand verbal and written instructions and will adhere to all study schedules and requirements.

    4. Subject is able to keep accurate seizure diaries.

Exclusion criteria

Exclusion Criteria:

- 1. Subject met any of the withdrawal criteria while in Study CB03-154-EP201. 2. Subject has any medical condition, personal circumstance, or ongoing AE (from Study CB03-154-EP201) that, in the opinion of the investigator, exposes the subject to unacceptable risk by participating in the study, or prevents adherence to the protocol.

3. Subject is planning to enter a clinical study with a different drug or planning to use any experimental device for treatment of epilepsy during the study and until 28 days after completion of this study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    The Subjects from CB03-154-EP201

    The subjects who completed the CB03-154-EP201 will be enrolled and begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.

    Drug: CB03-154

Interventions

  • All enrolled subjects will begin with a two-week course of CB03-154 at 10 mg QD. Upon demonstrating good tolerability, the dose will be increased to 20 mg QD and continued for up to two years.

06

What researchers measure

Primary outcomes

  1. To assess the long-term tolerability and safety of CB03-154 in patients diagnosed with epilepsy.

    Severity and frequency of associated AEs/serious adverse events (SAEs)

    Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.

  2. To assess the long-term efficacy of CB03-154 in patients diagnosed with epilepsy.

    Median percent change (MPC) in monthly (28 days) seizure frequency from baseline (the end of the DBP of study CB03 154-EP201) to the entire treatment period.

    Time frame: In the entire period of the whole study, including a treatment period up to 2 years (104 weeks) and a post treatment follow-up period of 8 weeks.

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax).

    For all subjects, blood samples will be obtained at Week 2, Week 4, Week 13, and Week 26 for in the period of study for plasma concentration measurement.

    Time frame: In the Week 2±3 days , Week 4±3 days , Week 13±3 days , and Week 26±7 days.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Jan 2029, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Aug 14, 2025
Primary completionEst.
Jan 2029
CompletionEst.
Jun 2029
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07238868
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Aug 14, 2025
Primary completion
Jan 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 20, 2025

Study contacts

Terence O'Brien, professor
Contact
te.obrien@alfred.org.au
0390762029

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CB03-154

Start the discussion